Recap Of Monday’s Biotech Catalysts – End Of the Day Summary
The U.S. Food and Drug Administration (FDA) has announced clearance to Insulet’s (NASDAQ:PODD) Omnipod 5 Automated Insulin Delivery…
Kronos Bio Shares Fall After Initial-Stage Blood Cancer Study Takes-off
Kronos Bio (NASDAQ: KRON) has initiated patient dosing in a Phase 1b/2 clinical trial of lanraplenib in combination with gilteritinib in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia (AML).
Kronos Bio Announces First Patient Dosed In Phase 1b/2 Clinical Trial Of Lanraplenib In Combination With Gilteritinib In Acute Myeloid Leukemia
Kronos Bio, Inc. (NASDAQ:KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that the first patient has been dosed in a Phase 1b/2 clinical trial of lanraplenib in
Kronos Bio, Invivoscribe Partner On Companion Diagnostic For Use With Entospletinib, Kronos Bio’s Investigational Compound Being Developed For Patients With AML
Kronos Bio, Inc. (NASDAQ:KRON), a company dedicated to transforming the lives of those affected by cancer, and Invivoscribe, a global provider of diagnostic kits and services for oncology, today announced their agreement
Kronos Bio Q2 EPS $(0.59) Down From $(0.53) YoY
Kronos Bio (NASDAQ:KRON) reported quarterly losses of $(0.59) per share. This is a 11.32 percent decrease over losses of $(0.53) per share from the same period last year.
